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THE MOLECULAR 
BASIS OF CANCER 
fter cardiovascular diseases, cancer is 
the second leading cause of death in 
America. Since 1990 over half a million 
Americans have died each year of some 
form of cance1; and the number and rate 
is still increasing. In 1970 approximately 
17 percent of all deaths were attributed 
to cancer, while by 1995 the figure had 
risen to 24 percent. In her chilling book 
on the meaning of illness in America, 
Illness as Metaphor, Susan Sontag 
described cancer as the sickness of the 
Am.erican 20th century. Learning about 
cancer has become more than a useful 
chore for those who suffer from the 
disease or wish to cope with the diseases 
of family members and loved ones. It is 
increasingly a matter of cultural literacy 
to com.e to understand the workings of a 
disease whose consequences seem to spare 
none of us. In the following essay, Frank 
Gorga, Assistant Professor of Chemistry, 
summarizes some of the most recent 
scientific thinking on the basic nature 
of cancer. 
BY FRANK GORGA 
INTRODUCTION 
Approximately three decades of inten-
sive research have led to an explosion 
in our knowledge of the molecular 
and cellular basis of cancer. Perhaps 
the most fundamental result of this 
research effort is the realization that 
cancer is a "genetic" disease. I use the 
term "genetic" in a broad fashion. 
"Genetic disease" is generally taken 
to mean an inherited or inheritable 
condition. In a broader sense a genetic 
disease results from changes to an 
organism's genetic material (i.e. its 
DNA). The expression of oncogenes 
(literally "cancer genes") within cells 
is a crucial event in the ea rly stages of 
tumor formation. Oncogenes can arise 
in cells via two mechanisms: infection 
of cells by tumor viruses and conver-
sion (mutation) of cellular protoonco-
genes to oncogenes. These discoveries 
and their implications for the preven-
tion, detection and treatment of cancer 
are discussed below. 
BASIC TUMOR BIOLOGY 
Tumors are masses of cells that have 
escaped the normal mechanisms that 
strictly regulate and limit the growth of 
most cells in an animal. The formation 
of a clinically recognizable tumor is a 
multi -step process. Tumors are thought 
to originate via the oncogenic transfor-
mation of a single cell. Once a cell is 
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transformed it has gained the ability to 
grow uncontrollably and microscopic 
patches of transformed cells (cancer in 
situ, to the pathologists) form. In order 
to progress to a clinically significant 
(macroscopic) tumor the transformed 
cells must be able to avoid the immune 
system. In some cases, the ability to 
cause angiogenesis (i.e. to stimulate the 
growth of blood vessels) is also impor-
tant in progression to a clinically signif-
icant tumor. Relatively late in their 
existence, some tumors gain the ability 
to escape from the site of their initial 
derivation and invade other areas of the 
body. This is the process of metastasis. 
Each of these processes, oncogenic 
transformation, ability to escape recog-
nition by the immune system, angio-
genesis and development of metastatic 
potential, are associate with genetic 
changes. Herein, we will concentrate on 
the genetic changes associated with 
oncogenic transformation. 
THE GENETIC BASIS OF TUMORS 
The earliest evidence for the genetic 
basis of tumors is probably the discov-
ery in 1911 by Peyton Rous that sarco-
mas (solid tumors) in chickens could 
be transmitted between animals using 
a "cell-free filtrate ." The active agent in 
this "cell-free filtrate" was found to be a 
virus called, aptly, Rous sarcoma virus. 
If one takes the view that a virus is a 
small "package of genes" with the abil-
ity to infect an appropriate host cell and 
thereby add the viral genes to the host 
cell, then one arrives at the simple 
conclusion that tumors can be caused 
by the addition (and, presumably, 
subsequent expression) of genetic 
material (i.e. viral DNA) to cells. 
In the years since Rous' work numer-
ous other tumor viruses, infecting vari-
ous animals, have been discovered. 
The significance of"tumor viruses" to 
human disease went unappreciated 
and, in fact, was hotly debated for a 
number of years. The moral and ethical 
difficulty in performing the experiment 
of infecting a human with a tumor-
causing agent makes it impossible to 
directly "prove" that a specific virus 
causes tumors in humans. However, 
molecular epidemiological studies tliat 
demonstrate the presence of a specific 
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THE CENTRAL DOGMA OF BIOLOGY 
Genetic information is stored as the sequence of bases in deoxyribonucleic acid 
(DNA) within the nucleus of each cell. The expression of genetic information 
begins with the synthesis of a messenger RNA molecule (mRNA) whose sequences 
of bases is coincide with that of the gene. Proteins are synthesized by "reading" 
the bases three at a time and "translating" the mRNA molecule into the amino 
acid sequence of the encoded protein. The e,,,_'Pression of genes is under very tight 
temporal and spatial control. Changes in the expression of genes result in changes 
in the functioning of cells, and ultimately in physiologic changes. Alteration of 
the bases within a gene (mutations) result in changes to the encoded protein and, 
ultimately, in changes in function. 
many individuals provide circumstan-
tial evidence that some human tumors 
are the result of viral infection. This 
type of correlation has, perhaps, been 
most clearly shown in the in the case of 
human papilloma virus and cervical 
carcinoma as well as Epstein Barr virus 
and Burketts lymphoma. 
There are a large number of human 
and animal tumors that are not associ-
ated with viral infection. The evidence 
that these tumors also have a genetic 
basis comes from three lines of inquiry. 
First, was the realization by Bruce Ames 
and others that many (most) carcino-
gens are also mutagens. That is, agents 
(including chemicals and radiation) 
that are known to cause cancer are also 
able to cause damage to DNA. The fact 
that damage to DNA can cause cancer 
led investigators to (cautiously) 
propose that the mutation of normal 
cellular genes might play a role in 
causing tumors. Further evidence 
supporting this hypothesis comes from 
applying the tools of molecular genetics 
to tumor biology. 
Secondly, during the 1970's and '80's, 
virologists studying Rous sarcoma 
virus were able to show that a single 
viral gene among the roughly half 
dozen total was responsible for tumori-
genesis by these viruses. This oncogene 
(i.e. "cancer causing gene") was named 
src (short for "sarcoma") . In 1981, 
Michael Bishop and Harold Varmus 
made the surprising discovery that nor-
mal (i.e. non-tumor) cells contained a 
gene that was related to the viral src 
gene. This normal cellular gene, called 
cellular src (c-src), is a member of a 
family of genes called protooncogenes. 
Lastly, in 1978, Robert Weinberg and 
coworkers demonstrated that there 
were oncogenes present in tumors of 
non-viral origin. This question was 
answered by a simple, elegant gene 
transfer e,,,_'Periment in which DNA iso-
lated from tumor cells was used to con-
vert oncogenically transformed normal 
cells in culture (see side bar "Gene 
Transfer"). This experiment clearly 
demonstrated the presence of onco-
genes in the large majority of tumors. 
Thus, our current understanding 
is that tumor formation is initiated by 
the expression of an oncogene within 
a cell. This expression can be brought 
about in two ways. Infection with a 
tumor virus and subsequent expression 
of viral genes, including the viral 
oncogene, is the cause of relatively few 
tumors. Most tumors are caused by 
the conversion (via mutation) of a 
subset of normal cellular genes, the 
protooncogenes, into oncogenes. 
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THE BIOLOGICAL ROLE OF 
PROTOONCOGENE PRODUCTS 
The discovery of protooncogenes in 
normal cells raises questions regarding 
their role in normal cellular processes. 
Are protooncogenes silently sitting 
within normal cells "waiting" to cause 
cancer, or do these genes play a role in 
normal physiological processes< The 
fact that the protein products of pro-
tooncogenes are expressed in (at least 
some) normal cells argues strongly for 
the latter. Research into the detailed 
functioning of many individual proto-
oncogenes has invariably described a 
role for the gene and its product in 
some physiological process. The 
processes in which protooncogenes are 
involved is quite varied; however, most 
protooncogenes have been found to be 
involved (not surprisingly) in the 
mechanisms that govern the growth 
and differentiation of cells. The bio-
chemical function of protooncogene 
products is even more varied. Proto-
oncogenes encoding protein products 
that serve as circulating growth factors 
and as cell surface receptors for these 
growth factors have been discovered. 
Many protooncogene products have 
been found to serve as components of 
the intracellular signal transduction 
pathways that serve to transmit the 
"signal" generated by growth factors 
from the cell surface to the nucleus in 
order to effect the changes in gene 
expression needed for cellular division. 
lMPLLCATLONS FOR THE 
0LAGNOSLS AND PREVENTION 
OF CANCER 
The discovery of protooncogenes and 
their mutation to oncogenic forms has 
caused a profound change in the way 
we think about cancer prevention and 
diagnosis. The fact that the ultimate 
cause of cancer is genetic change 
(mutation) suggests that prevention 
of cancer is "simply" a matter of elimi-
nating our exposure to mutagens 
(agents that cause mutation) . However, 
it is impossible to exist without some 
exposure to mutagens. Mutagens, 
including cosmic and other radiation, 
as well as some mutagenic chemicals, 
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DEMONSTRATION Of 
ONCOGENES BY GENE TRANSFER 
DNA, isolated from tumor cells (grow-
ing in culture) , is mixed with calcium 
phosphate and added to normal mouse 
cells under conditions where the DNA 
can enter the cells (this process is called 
transfection). If an oncogene is present 
in the DNA, a small number of the 
normal cells will become oncogenically 
transformed (i.e. "tumor-like") . If 
these transformed cells are isolated 
and injected into a mouse, they grow 
to form a tumor. 
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Eliminating exposure to these agents 
is physically impossible. Thus, onco-
genic mutation and cancer must be 
considered to be a (partially) natural 
phenomenon. The "best" we can hope 
for is to minimize, taking into account 
the economic and social costs, our 
exposure to mutagens that result from 
human activity and thus minimize the 
frequency of oncogenic mutations. 
The discovery of oncogenic muta-
tions also helps to explain the obser-
vation that incidence of cancer, in 
general, rises with age. Simply, given a 
constant (or nearly constant) rate of 
mutation , the longer people live the 
greater the chance that they will suffer 
an oncogenic mutation somewhere in 
their bodies. 
The existence of oncogenic muta-
tions opens new possibilities in the 
detection of cancer. Currently, most 
cancers are detected indirectly by the 
symptoms they cause. Thus, tumors 
must be large enough to "cause 
problems" before they are detected . 
However, the earlier a tumor is 
detected, the smaller it is, and the less 
likely it will have spread to other tissues 
(metastasize); thus the more "curable" 
the tumor is. If one can design specific 
molecular-level probes for oncogenes 
or their products, it should be possible 
to devise a diagnostic test that may 
allow earlier and more accurate 
detection of tumors. One (somewhat 
controversial) example of this idea is 
the test for prostate-specific antigen 




The discovery of protooncogenes and 
their varied functions has also dramati-
cally changed our view of anti-tumor 
therapy. Most current anti-tumor ther-
apies (including chemotherapeutic 
drugs and radiation treatments) are not 
"anti-tumor" per se. These treatments 
target rapidly growing cells and thus 
affect a number of normal tissues in 
addition to tumors, thereby causing the 
side effects associated with anti-tumor 
therapy (see side bar "Anti -tumor 
Therapy"). Discovery of oncogenes 
and the gaining of detailed information 
about the biochemical activity of their 
products is both discouraging and 
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encouraging in terms of anti-tumor 
therapy. The (relatively) large number 
of oncogenes underscores the fact that 
"cancer" is not a single disease and 
means that there will be no "magic 
bullet" that will cure all (or even most) 
tumors. On the other hand, each 
known oncogene, and its product, 
represents a known potential target for 
anti-tumor therapy. Development of 
drugs that specifically interfere with 
the activity of a particular oncogene 
product should allow more effective 
treatment of the tumors caused by 
expression of that particular oncogene, 
including a large decrease in the side 
effects of the anti-tumor therapy. In 
addition, "anti-sense" therapy designed 
to specifically disrupt the expression 
of oncogenes represents a powerful 
new, although unproven, approach to 
anti-tumor therapy. 
SIDE EFFECTS OF 
ANTI-TUMOR THERAPY 
Anti-tumor radiation treatment 
and most current chemotherapy 
drugs work by interfering with 
DNA replication or some other 
aspect of cellular division. Thus 
these agents do not specifically 
target tumor cells; rather they kill 
both tumor cells and normal 
cells that happen to grow rapidly. 
One consequence of tl1is lack of 
specificity is the side effects of 
cancer treatment. Although most 
cells in the adult body do not 
grow, or do so slowly, there are 
tissues whose function requires 
the regular replenishment of 
cells. These tissues contain popu-
lations of cells that grow rapidly 
during the course of normal 
functioning. Many of the side 
effects of anti-tumor therapy, 
including loss of hair, nausea and 
immunosupression, are directly 
attributable to disruption of 
rapidly growing cell populations 
in hair follicles, the intestines, 
and bone marrow, respectively. 
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A~m-SENSE TECHNOLOGY 
Much of nucleic acid structure and function is based on base-pairing interactions 
between the building blocks (bases) of DNA and RNA. These complementary 
interactions are specific in that within a DNA molecule adenine (A) always pairs 
with thymidine (T) and guanine (G) always pairs with cytidine (C). In RNA, thymi-
dine is replaced with uracil (U), which also pairs with adenine, but the "rules" of 
bases pairing are otherwise the same. Anti-sense technology is a method for dis-
rupting the expression of a specific protein with in cells. This technology involves 
the introduction (into a cell) of an anti-sense DNA that is complementary to the 
mRNA that encodes the protein of interest. This anti-sense DNA binds specifically 
to the mRNA (via specific base pairing) and inhibits its translation into protein. 
Thus, this technology allows the specific disruption of the production of a single 
protein within cells. Although anti-sense technology is currently useful in the lab, 
the technology for delivery of anti-sense DNA's in whole organisms is still under 
development. Once the technology is fully developed, disruption of oncogene 
expression using this technique should be an effective anti-tumor therapy. 
CONCLUSION 
That three decades of intensive research 
in oncology and related basic sciences 
has not led to a cure for cancer may 
seem disappointing to the general 
public; it has, however, led scientists 
to a much better understanding of the 
"problem" of cancer. The discovery 
of the genetic basis for tumorigenesis, 
along with the advent of"biotech-
nology" holds great promise that the 
next thirty years will bring both more 
effective anti-tumor therapies and 
greatly improved diagnosis 
of tumors. 




This web site (maintained by the 
National Cancer Institute) has infor-
mation on cancer at all levels. Material 
appropriate for patients (and other 
non-specialists) is maintained, as well 
as specialized information for health 
professionals and basic researchers. 
• Scientific American , 
September 1996 
(http: //www.sciam .com/0996issue/ 
0996currentissue.html) 
This special issue of Scientific 
American titled "What You Need To 
Know About Cancer" has numerous 
articles dealing, in more detail, with 
many of the issues covered herein. 
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· Nobel Prizes 
Two Nobel Prizes have been awarded 
for work related to tumor viruses and 
oncogenes. The 1975 Nobel Prize in 
Physiology or Medicine was awarded 
jointly to David Baltimore, Renato 
Dulbecco and Howard Temin "for their 
discoveries concerning the interaction 
between tumour viruses and the 
genetic material of the cell'.' More 
information can be found at the Nobel 
Foundation's web site (http://www. 
nobel.se/laureates/medicine-1975. 
html ). In 1989, the Nobel Prize for 
Physiology or Medicine was awa rded 
jointly to J. Michael Bishop and Harold 
Varmus, "for their discovery of the 
cellular origin of retroviral oncogenes" 
(http://www.nobel.se/laureates/ 
medicine-1989.html). Bishop's (Biosci 
Rep. 10(6): 473-491, 1990) and Varmus' 
(Biosci Rep. 10(5) : 413-430, 1990) 
acceptance speeches were published 
in Bioscience Reports. 
Frank Gorga is Assistant Professor of 
Chemical Sciences 
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